文献速递血栓与止血

低/中剂量凝血因子Ⅷ对30例成人重型血友病A患者疗效的单中心分析

[Analysis of the effects of low/intermediate dose of coagulation factor Ⅷ on 30 adult patients with severe hemophilia A in a single center].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

纳入南京大学医学院附属南京鼓楼医院30例成人重型血友病A患者(低剂量预防组20例、中剂量预防组10例),回顾性分析低/中剂量FⅧ预防治疗前后ABR、AJBR、靶关节数量、FISH、生活质量及SF-36评分。中位随访48个月,两方案较按需治疗均显著降低出血并改善功能与生活质量,中剂量组出血改善优于低剂量组。

要点

  • 低、中剂量FⅧ预防治疗较按需治疗可降低成人重型血友病A患者ABR、AJBR及靶关节数量(P<0.05)。
  • 中剂量预防组在ABR、AJBR及靶关节数量改善上优于低剂量预防组(P<0.05)。
  • 两组FISH、生活质量及SF-36评分较按需治疗均改善,但两组间差异无统计学意义(P>0.05)。

核心结论

  • 低、中剂量FⅧ预防治疗较按需治疗可明显降低成人重型血友病A患者出血频率、延缓关节病变进展并提高生活质量。
  • 中剂量预防组在临床出血改善方面优于低剂量预防组。

研究设计与样本

  • 回顾性分析纳入南京大学医学院附属南京鼓楼医院接受低/中剂量FⅧ预防治疗的30例成人重型血友病A患者,其中低剂量预防组20例、中剂量预防组10例。
  • 比较预防治疗前(按需治疗时)与预防治疗后的ABR、AJBR、靶关节数量、FISH评分、生活质量评分及SF-36评分,中位随访48个月。

主要发现

  • 与预防前按需治疗时相比,低剂量预防组和中剂量预防组的ABR、AJBR、靶关节数量均明显降低(P<0.05),且中剂量预防组改善优于低剂量预防组(P<0.05)。
  • 与按需治疗时相比,低、中剂量预防治疗后FISH评分、生活质量评分及SF-36评分均明显改善(原文此处写作P>0.05,按上下文应为P<0.05),但低剂量预防组与中剂量预防组之间以上指标差异无统计学意义(P>0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical effects of low- and intermediate-dose factor Ⅷ (F Ⅷ) prophylaxis in Chinese adult patients with severe hemophilia A. Methods: Thirty adult patients with severe hemophilia A who received low- (n=20) /intermediate-dose (n=10) F Ⅷ prophylaxis at Nanjing Drum Tower Hospital affiliated with Nanjing University Medical College were included in the study. The annual bleeding rate (ABR), annual joint bleeding rate (AJBR), number of target joints, functional independence score of hemophilia (FISH), quality of life score, and health status score (SF-36) before and after preventive treatment were retrospectively analyzed and compared. Results: The median follow-up was 48 months. Compared with on-demand treatment, low- and intermediate-dose prophylaxis significantly reduced ABR, AJBR, and the number of target joints (P<0.05) ; the improvement in the intermediate-dose prophylaxis group was better than that in the low-dose prophylaxis group (P<0.05). Compared with on-demand treatment, the FISH score, quality of life score, and SF-36 score significantly improved in both groups (P<0.05), but there was no significant difference between the two groups (P>0.05) . Conclusion: In Chinese adults with severe hemophilia A, low- and intermediate-dose prophylaxis can significantly reduce bleeding frequency, delay the progression of joint lesions, and improve the quality of life of patients as compared with on-demand treatment. The improvement in clinical bleeding was better with intermediate-dose prophylaxis than low-dose prophylaxis. 目的: 评估低/中剂量凝血因子Ⅷ(FⅧ)预防治疗在成人重型血友病A患者中的疗效。 方法: 纳入在南京大学医学院附属南京鼓楼医院接受低/中剂量FⅧ预防治疗的30例成人重型血友病A患者(低剂量预防组20例、中剂量预防组10例),对预防治疗前、后的年出血次数(ABR)、年关节出血次数(AJBR)、靶关节数量、血友病功能独立性评分(FISH)、生活质量评分及健康状况评分(SF-36)进行回顾性分析、比较。 结果: 中位随访48个月。与预防前按需治疗时相比,低、中剂量预防治疗组ABR、AJBR、靶关节数量均明显降低(P<0.05),且中剂量预防治疗组改善优于低剂量预防治疗组(P<0.05)。低、中剂量预防治疗后与按需治疗时相比,患者的FISH评分、生活质量评分及SF-36评分均明显改善(P>0.05),但低剂量预防组和中剂量预防组之间以上指标差异无统计学意义(P>0.05)。 结论: 低、中剂量FⅧ预防治疗较按需治疗可明显降低重型血友病A患者出血频率,延缓关节病变的进展,提高患者生活质量。中剂量预防组临床出血改善方面优于低剂量预防组。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yuan YH, Xu PP, Xu YY, et al. [Analysis of the effects of low/intermediate dose of coagulation factor Ⅷ on 30 adult patients with severe hemophilia A in a single center]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 36987721. doi:10.3760/cma.j.issn.0253-2727.2023.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。